Is the streptomycin‑ethambutol‑levofloxacin (SEL) bridging regimen considered a tuberculosis treatment?

Does bridging therapy, SEL consider as TB treatment?

No—streptomycin–ethambutol–levofloxacin (SEL) alone is not an adequate tuberculosis treatment regimen and should not be used as “bridging” therapy except in rare, short, expert‑supervised scenarios when first‑line drugs are truly unavailable or contraindicated. 1, 2, 3

• What constitutes TB treatment (to reduce mortality, morbidity, and preserve quality of life):

  • Drug-susceptible TB requires a rifamycin- and isoniazid‑based regimen: classically 2 months of isoniazid + rifampin + pyrazinamide + ethambutol, then 4 months of isoniazid + rifampin (total 6 months), or validated modern 4‑month option with rifapentine + isoniazid + pyrazinamide + moxifloxacin in eligible patients 1, 2, 3.
  • Streptomycin is not interchangeable with ethambutol unless susceptibility is known and even then is not a core drug; fluoroquinolone (e.g., levofloxacin) is not part of standard first‑line DS‑TB regimens and its addition without rifamycin/INH risks failure and resistance 2, 1.

• When could SEL appear:

  • Isoniazid‑resistant, rifampin‑susceptible TB: WHO recommends rifampin + ethambutol + pyrazinamide + levofloxacin for 6 months—note this includes rifampin and pyrazinamide; streptomycin is not recommended to add. SEL without rifampin/PZA does not meet this standard 4.
  • MDR/RR‑TB: Regimens require at least 4–5 effective drugs anchored by group A/B agents (fluoroquinolone, bedaquiline, linezolid, etc.); streptomycin has limited role, and a 3‑drug SEL is grossly insufficient and unsafe 5, 4.

• Practical algorithm (what to do instead of SEL):

  1. If drug-susceptible TB suspected/confirmed: start HRZE for 2 months then HR for 4 months, or 4‑month rifapentine–moxifloxacin regimen where indicated 1, 2.
  2. If INH‑resistant, RIF‑susceptible: use RIF + EMB + PZA + levofloxacin for 6 months; do not add streptomycin 4.
  3. If MDR/RR‑TB likely/confirmed: construct an individualized regimen with at least 4 effective drugs per WHO (include a fluoroquinolone plus bedaquiline and linezolid when feasible) 4, 5.
  4. If temporary “bridge” absolutely unavoidable (e.g., severe intolerance, no oral access): use the minimum time necessary and urgently transition to a guideline‑concordant regimen; avoid monotherapy/dual therapy and avoid SEL as a 3‑drug stand‑in because it lacks rifamycin/INH backbone and promotes resistance, worsening outcomes 2, 1.

• Pitfalls/caveats to avoid:

  • Do not use three‑drug non‑rifamycin regimens (e.g., SEL) for HIV or non‑HIV TB; such regimens are linked to failure and must be 18+ months if used at all—still inferior and not recommended 6.
  • Adding a single drug to a failing or partial regimen accelerates resistance; never “bridge” with underpowered combinations 3.
  • Streptomycin resistance is common; its role is limited and should not replace rifamycin/INH backbones 2.
  • If INH‑resistant and RIF‑susceptible, follow WHO regimen including RIF and PZA; SEL omits essentials and is not acceptable 4.

Most recent, highest‑quality guidance prioritizing outcomes: 2025 ATS/CDC/ERS/IDSA guideline (validates 4‑month rifapentine–moxifloxacin regimen and reaffirms rifamycin/INH‑based standards) and WHO 2021 DR‑TB update (defines levofloxacin’s role in Hr‑TB with RIF and PZA, and MDR/RR‑TB constructs). Both make clear that SEL alone is not TB treatment and risks higher mortality, morbidity, and worse quality of life through resistance and relapse 1, 4.